WO2006002114A3 - Tumor-associated antigen profiles in cancer diagnostics and immunotherapy - Google Patents

Tumor-associated antigen profiles in cancer diagnostics and immunotherapy Download PDF

Info

Publication number
WO2006002114A3
WO2006002114A3 PCT/US2005/021836 US2005021836W WO2006002114A3 WO 2006002114 A3 WO2006002114 A3 WO 2006002114A3 US 2005021836 W US2005021836 W US 2005021836W WO 2006002114 A3 WO2006002114 A3 WO 2006002114A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
tumor
associated antigen
cancer diagnostics
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/021836
Other languages
French (fr)
Other versions
WO2006002114A2 (en
Inventor
Chih-Sheng Chiang
John J L Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35478743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006002114(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002571070A priority Critical patent/CA2571070A1/en
Priority to AU2005258014A priority patent/AU2005258014B2/en
Priority to DE602005023488T priority patent/DE602005023488D1/en
Priority to AT05766030T priority patent/ATE480776T1/en
Priority to DK05766030.0T priority patent/DK1782070T3/en
Application filed by Mannkind Corp filed Critical Mannkind Corp
Priority to JP2007516827A priority patent/JP2008503498A/en
Priority to MXPA06014771A priority patent/MXPA06014771A/en
Priority to EP05766030A priority patent/EP1782070B1/en
Priority to US11/323,964 priority patent/US20060159689A1/en
Publication of WO2006002114A2 publication Critical patent/WO2006002114A2/en
Publication of WO2006002114A3 publication Critical patent/WO2006002114A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed herein are methods for matching a cancer condition with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for confirming diagnosis of a particular type of cancer. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs to optimize the match between a patient's cancer condition and available immunotherapies.
PCT/US2005/021836 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy Ceased WO2006002114A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP05766030A EP1782070B1 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
MXPA06014771A MXPA06014771A (en) 2004-06-17 2005-06-17 TUMOR ASSOCIATED ANTIGEN PROFILES IN CANCER DIAGNOSTICS AND IMMUNOTHERAPY.
DE602005023488T DE602005023488D1 (en) 2004-06-17 2005-06-17 TUMOR ASSOCIATED ANTIGEN PROFILES IN CANCER DIAGNOSIS AND IMMUNOTHERAPY
AT05766030T ATE480776T1 (en) 2004-06-17 2005-06-17 TUMOR-ASSOCIATED ANTIGEN PROFILES IN CANCER DIAGNOSTICS AND IMMUNOTHERAPY
DK05766030.0T DK1782070T3 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnosis and immunotherapy
CA002571070A CA2571070A1 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
JP2007516827A JP2008503498A (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnosis and immunotherapy
AU2005258014A AU2005258014B2 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
US11/323,964 US20060159689A1 (en) 2004-06-17 2005-12-29 Combinations of tumor-associated antigens in diagnostics for various types of cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58096904P 2004-06-17 2004-06-17
US60/580,969 2004-06-17

Publications (2)

Publication Number Publication Date
WO2006002114A2 WO2006002114A2 (en) 2006-01-05
WO2006002114A3 true WO2006002114A3 (en) 2006-10-05

Family

ID=35478743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021836 Ceased WO2006002114A2 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy

Country Status (10)

Country Link
EP (1) EP1782070B1 (en)
JP (1) JP2008503498A (en)
AT (1) ATE480776T1 (en)
AU (1) AU2005258014B2 (en)
CA (1) CA2571070A1 (en)
DE (1) DE602005023488D1 (en)
DK (1) DK1782070T3 (en)
ES (1) ES2351995T3 (en)
MX (1) MXPA06014771A (en)
WO (1) WO2006002114A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10494432B2 (en) 2007-07-16 2019-12-03 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US10544218B2 (en) 2008-01-31 2020-01-28 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US10981987B2 (en) 2007-07-16 2021-04-20 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
US11000510B2 (en) 2014-09-23 2021-05-11 Genentech, Inc. Methods of using anti-CD79b immunoconjugates

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
PL1833506T3 (en) * 2004-12-29 2016-01-29 Mannkind Corp Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2007140958A2 (en) * 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
GB0720118D0 (en) * 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
JP2011512415A (en) * 2008-02-20 2011-04-21 アリゾナ バイオメディカル リサーチ コミッション Use of therapeutic peptides for the treatment and prevention of cancer
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
US10066004B2 (en) 2010-10-12 2018-09-04 Arizona Cancer Therapeutics, Llc EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3
CA2814670A1 (en) 2010-10-12 2012-04-19 Arizona Biomedical Research Commission Egfr-based peptides
BR112013014527A2 (en) 2010-12-20 2017-03-07 Genentech Inc isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, use of immunoconjugate, method for treating an individual who has mesothelin positive cancer, for inhibiting proliferation of a mesothelin positive cell, for detecting human mesothelin in a biological sample and for detecting mesothelin positive cancer
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
WO2014074785A1 (en) * 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
IL260030B2 (en) 2016-01-08 2025-12-01 Nykode Therapeutics ASA Neoepitope therapeutic vaccine against cancer
US10436771B2 (en) * 2016-04-05 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for targeted therapy based on single-cell stimulus perturbation response
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
CA3150273A1 (en) * 2019-08-08 2021-02-11 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
DE10225139A1 (en) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Methods for the identification of immunoreactive peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GOLD D V ET AL: "DIFFERENTIAL EXPRESSION OF TUMOR ASSOCIATED ANTIGENS IN HUMAN COLON CARCINOMAS XENO GRAFTED INTO NUDE MICE", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 71, no. 1, 1983, pages 117 - 124, XP008057919 *
LEWIS J J ET AL: "DEFINITION OF TUMOR ANTIGENS SUITABLE FOR VACCINE CONSTRUCTION", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHIA, PA, US, vol. 6, December 1995 (1995-12-01), pages 321 - 327, XP002926806, ISSN: 1044-579X *
NEUMANN ELENA ET AL: "Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies?", CANCER RESEARCH, vol. 58, no. 18, 15 September 1998 (1998-09-15), pages 4090 - 4095, XP002361281, ISSN: 0008-5472 *
SCANLAN M J ET AL: "Challenges to the development of antigen-specific breast cancer vaccines.", BREAST CANCER RESEARCH : BCR. 2001, vol. 3, no. 2, 2001, pages 95 - 98, XP002361282, ISSN: 1465-5411 *
VRIES DE T J ET AL: "HETEROGENOUS EXPRESSION OF IMMUNOTHERAPY CANDIDATE PROTEINS GP100, MART-1 AND TYROSINASE IN HUMAN MELANOMA CELL LINES AND IN HUMAN MELANOCYTIC LESIONS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, 1 August 1997 (1997-08-01), pages 3223 - 3229, XP002952165, ISSN: 0008-5472 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10494432B2 (en) 2007-07-16 2019-12-03 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US10981987B2 (en) 2007-07-16 2021-04-20 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
US11866496B2 (en) 2007-07-16 2024-01-09 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
US10544218B2 (en) 2008-01-31 2020-01-28 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US11000510B2 (en) 2014-09-23 2021-05-11 Genentech, Inc. Methods of using anti-CD79b immunoconjugates

Also Published As

Publication number Publication date
AU2005258014B2 (en) 2012-07-12
AU2005258014A1 (en) 2006-01-05
DK1782070T3 (en) 2011-01-03
WO2006002114A2 (en) 2006-01-05
ATE480776T1 (en) 2010-09-15
MXPA06014771A (en) 2007-03-21
CA2571070A1 (en) 2006-01-05
DE602005023488D1 (en) 2010-10-21
EP1782070B1 (en) 2010-09-08
ES2351995T3 (en) 2011-02-14
EP1782070A2 (en) 2007-05-09
JP2008503498A (en) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2006002114A3 (en) Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
EP2433954B8 (en) Identification of tumor-associated antigens for diagnosis and therapy
WO2006011810A3 (en) Mr imaging method for the discrimination between healthy and tumour tissue
WO2005003298A3 (en) Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
WO2006082406A3 (en) Human antibodies and proteins
WO2007115045A3 (en) Diagnostics and treatments for tumors
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto
WO2005010048A3 (en) Rg1 antibodies and uses thereof
WO2006020773A3 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
WO2003039462A3 (en) B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2004032857A3 (en) Antibody therapy
WO2006084075A3 (en) Adam-9 modulators
WO2003055917A3 (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2010054377A3 (en) Fully human antibodies against n-cadherin
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2007022511A3 (en) Listeria-induced immunorecruitment and activation, and methods of use thereof
WO2006083852A3 (en) Luca2 and antibodies that bind thereto
WO2006076584A3 (en) Kid31 and antibodies that bind thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/014771

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2571070

Country of ref document: CA

Ref document number: 2007516827

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005258014

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005766030

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005258014

Country of ref document: AU

Date of ref document: 20050617

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005258014

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005766030

Country of ref document: EP